JP2019501202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501202A5 JP2019501202A5 JP2018535880A JP2018535880A JP2019501202A5 JP 2019501202 A5 JP2019501202 A5 JP 2019501202A5 JP 2018535880 A JP2018535880 A JP 2018535880A JP 2018535880 A JP2018535880 A JP 2018535880A JP 2019501202 A5 JP2019501202 A5 JP 2019501202A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- inhibitor
- reverse transcriptase
- capsid
- immunostimulants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065611A JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276722P | 2016-01-08 | 2016-01-08 | |
| US62/276,722 | 2016-01-08 | ||
| US201662343514P | 2016-05-31 | 2016-05-31 | |
| US62/343,514 | 2016-05-31 | ||
| US201662345476P | 2016-06-03 | 2016-06-03 | |
| US62/345,476 | 2016-06-03 | ||
| US201662409180P | 2016-10-17 | 2016-10-17 | |
| US62/409,180 | 2016-10-17 | ||
| US201662420969P | 2016-11-11 | 2016-11-11 | |
| US62/420,969 | 2016-11-11 | ||
| PCT/US2017/012614 WO2017120527A2 (en) | 2016-01-08 | 2017-01-06 | Therapeutic compositions and methods for treating hepatitis b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065611A Division JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501202A JP2019501202A (ja) | 2019-01-17 |
| JP2019501202A5 true JP2019501202A5 (https=) | 2020-02-20 |
Family
ID=59274445
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535880A Pending JP2019501202A (ja) | 2016-01-08 | 2017-01-06 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2022065611A Pending JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A Pending JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065611A Pending JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A Pending JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190282604A1 (https=) |
| EP (1) | EP3400008A4 (https=) |
| JP (3) | JP2019501202A (https=) |
| KR (2) | KR20180120675A (https=) |
| CN (1) | CN110022895A (https=) |
| AU (3) | AU2017205650A1 (https=) |
| BR (1) | BR112018013928A2 (https=) |
| CA (1) | CA3009996A1 (https=) |
| CL (2) | CL2018001858A1 (https=) |
| CO (1) | CO2018008249A2 (https=) |
| HK (1) | HK1255835A1 (https=) |
| IL (2) | IL295692A (https=) |
| PH (1) | PH12018501455A1 (https=) |
| SG (2) | SG10201912314QA (https=) |
| TW (4) | TW201735950A (https=) |
| WO (1) | WO2017120527A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4512407A3 (en) | 2018-07-13 | 2025-09-24 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating rtel1 expression |
| US20200332297A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| MA55720A (fr) * | 2019-04-18 | 2022-02-23 | Janssen Pharmaceuticals Inc | Polythérapie pour le traitement d'une infection par le virus de l'hépatite b |
| CN114828852A (zh) * | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| US12569500B2 (en) | 2020-05-15 | 2026-03-10 | Fujian Akeylink Biotechnology Co., Ltd. | Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV |
| JP2024537830A (ja) * | 2021-10-08 | 2024-10-16 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | カプシドタンパク質阻害剤と逆転写酵素阻害剤とを含む医薬組合せ |
| CN117771361B (zh) * | 2024-02-27 | 2024-06-07 | 天津中逸安健生物科技有限公司 | 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6809083B1 (en) * | 1998-02-12 | 2004-10-26 | Richard A. Mueller | Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections |
| WO2001045712A1 (de) * | 1999-12-22 | 2001-06-28 | Bayer Aktiengesellschaft | Arzneimittelkombinationen gegen virale erkrankungen |
| WO2004050613A2 (en) * | 2002-12-02 | 2004-06-17 | Gilead Sciences, Inc. | 2-substituted-3-propenamide derivatives and methods of using the same |
| US20110218512A1 (en) * | 2008-06-03 | 2011-09-08 | Aethlon Medical, Inc. | Enhanced antiviral therapy methods and devices |
| SG181633A1 (en) * | 2009-12-31 | 2012-07-30 | xiao-jian Zhou | Compositions and methods for treating hepatitis b virus infection |
| WO2012024170A2 (en) * | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2013308045B2 (en) * | 2012-08-30 | 2018-10-04 | Replicor Inc. | Methods for the treatment of hepatitis B and hepatitis D infections |
| US8993771B2 (en) * | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| CA2948580A1 (en) * | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
| US10550084B2 (en) * | 2017-12-04 | 2020-02-04 | Arbutus Biopharma Corporation | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same |
| US10358447B2 (en) * | 2017-12-04 | 2019-07-23 | Arbutus Biopharma Corporation | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same |
-
2017
- 2017-01-06 HK HK18114911.7A patent/HK1255835A1/zh unknown
- 2017-01-06 KR KR1020187022434A patent/KR20180120675A/ko not_active Ceased
- 2017-01-06 WO PCT/US2017/012614 patent/WO2017120527A2/en not_active Ceased
- 2017-01-06 US US16/068,243 patent/US20190282604A1/en not_active Abandoned
- 2017-01-06 BR BR112018013928-9A patent/BR112018013928A2/en not_active Application Discontinuation
- 2017-01-06 SG SG10201912314QA patent/SG10201912314QA/en unknown
- 2017-01-06 EP EP17736471.8A patent/EP3400008A4/en not_active Withdrawn
- 2017-01-06 CN CN201780014167.5A patent/CN110022895A/zh active Pending
- 2017-01-06 IL IL295692A patent/IL295692A/en unknown
- 2017-01-06 IL IL303754A patent/IL303754A/en unknown
- 2017-01-06 AU AU2017205650A patent/AU2017205650A1/en not_active Abandoned
- 2017-01-06 CA CA3009996A patent/CA3009996A1/en active Pending
- 2017-01-06 KR KR1020257018649A patent/KR20250089561A/ko active Pending
- 2017-01-06 JP JP2018535880A patent/JP2019501202A/ja active Pending
- 2017-01-06 SG SG11201805729SA patent/SG11201805729SA/en unknown
- 2017-01-09 TW TW106100606A patent/TW201735950A/zh unknown
- 2017-01-09 TW TW112146636A patent/TW202435851A/zh unknown
- 2017-01-09 TW TW110121989A patent/TW202211912A/zh unknown
- 2017-01-09 TW TW111130283A patent/TW202322791A/zh unknown
-
2018
- 2018-07-06 CL CL2018001858A patent/CL2018001858A1/es unknown
- 2018-07-06 PH PH12018501455A patent/PH12018501455A1/en unknown
- 2018-08-03 CO CONC2018/0008249A patent/CO2018008249A2/es unknown
-
2022
- 2022-04-12 JP JP2022065611A patent/JP2022087209A/ja active Pending
- 2022-06-02 AU AU2022203814A patent/AU2022203814A1/en not_active Abandoned
- 2022-11-29 US US18/071,353 patent/US20240050463A1/en active Pending
-
2023
- 2023-03-28 CL CL2023000892A patent/CL2023000892A1/es unknown
-
2024
- 2024-05-09 JP JP2024076451A patent/JP2024105468A/ja active Pending
-
2025
- 2025-08-14 AU AU2025217340A patent/AU2025217340A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501202A5 (https=) | ||
| Nilsson-Payant et al. | The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication | |
| WO2015042308A3 (en) | Rna-based hiv inhibitors | |
| JP2016531144A5 (https=) | ||
| Ouyang et al. | lncRNAs regulate the innate immune response to viral infection | |
| JP2019068829A5 (https=) | ||
| ZA202106848B (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| IL295692A (en) | Medical preparations and methods for treating jaundice b | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| JP2015528449A5 (https=) | ||
| CY1106207T1 (el) | Αντιιικα παραγωγα νουκλεοζιτων | |
| JP2006141398A5 (https=) | ||
| JP2019530462A5 (https=) | ||
| SA517382236B1 (ar) | نيوكليدات بيورين مستبدلة بـ 2- n6 معدل مستبدل بــــ بيتا-d-2´-ديوكسي-2´-ألفا-فلورو-2 ´-بيتا-c لمعالجة hcv | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| JP2017036288A5 (https=) | ||
| JP2017536344A5 (https=) | ||
| JP2016128507A5 (https=) | ||
| WO2010081082A3 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
| JP2016508134A5 (https=) | ||
| CN109952304A (zh) | 一类抑制并降解cdk的化合物 | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| JP2021505526A5 (https=) | ||
| EA201500748A1 (ru) | Ингибирующие олигонуклеотиды и их применение в терапии |